SELECT
Turned lenvatinib into the main drug for thyroid cancers that no longer take up radioactive iodine, quadrupling the time before the disease grew.
Median PFS 18.3 vs 3.6 months (HR 0.21); ORR 64.8% vs 1.5%. NEJM 2015; FDA approval February 2015. Hypertension in ~68% and a dose-reduction rate above 60% drive management; OS crossover-confounded.
- Median 18.3 vs 3.6 months with Lenvatinib compared with Placebo; about 14.7 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 79 percent lower chance of the event at any given time (hazard ratio 0.21).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 64.8 vs 1.5 out of 100 had their tumour shrink with Lenvatinib compared with Placebo; 63.3 more per 100.
- Roughly one extra person helped for every 2 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Radioiodine-refractory differentiated thyroid cancer with progression: lenvatinib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
392 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Lenvatinib | — | 18.3 months | 0.21 | — | link |
| Placebo | — | 3.6 months | ||||
| Objective response rate | Lenvatinib | — | 64.8% | — | — | link |
| Placebo | — | 1.5% |
Pages like this
not linked directly; found by shared links- TrialDECISION
Shares Radioiodine-refractory (RAI-R) thyroid cancer, VEGF / VEGFR, Thyroid cancer, Small-molecule kinase inhibitors.
- ProductVandetanib
Shares RET, VEGF / VEGFR, Thyroid cancer, Small-molecule kinase inhibitors.
- TrialARROW (thyroid cohorts)
Shares RET, Thyroid cancer, Small-molecule kinase inhibitors.
- TrialSANET-ep and SANET-p
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- PairingMAPK inhibitor redifferentiation → radioiodine
Shares Radioiodine-refractory (RAI-R) thyroid cancer, Thyroid cancer, Small-molecule kinase inhibitors.
- TrialLIBRETTO-531
Shares RET, Thyroid cancer, Small-molecule kinase inhibitors.
- ProductPazopanib
Shares Anti-angiogenic therapy, VEGF / VEGFR, Small-molecule kinase inhibitors.
- ProductPralsetinib
Shares RET, Thyroid cancer, Small-molecule kinase inhibitors.